PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
-4.31%
Cost reduction while Biotechnology median is 0.00%. Seth Klarman would investigate competitive advantage potential.
4.31%
Growth of 4.31% versus flat Biotechnology gross profit. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
4.88%
R&D change of 4.88% versus flat Biotechnology spending. Walter Schloss would verify adequacy.
-40.17%
G&A reduction while Biotechnology median is 0.00%. Seth Klarman would investigate efficiency gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.25%
Operating expenses reduction while Biotechnology median is -1.75%. Seth Klarman would investigate advantages.
-8.25%
Total costs reduction while Biotechnology median is -1.59%. Seth Klarman would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-4.31%
D&A reduction while Biotechnology median is 0.00%. Seth Klarman would investigate efficiency.
8.31%
EBITDA growth exceeding 1.5x Biotechnology median of 3.53%. Joel Greenblatt would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
8.25%
Operating income growth exceeding 1.5x Biotechnology median of 2.97%. Joel Greenblatt would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
133.19%
Other expenses growth exceeding 1.5x Biotechnology median of 2.66%. Jim Chanos would check for issues.
12.55%
Pre-tax income growth exceeding 1.5x Biotechnology median of 4.36%. Joel Greenblatt would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
175.66%
Tax expense change of 175.66% versus flat Biotechnology. Walter Schloss would verify strategy.
12.55%
Net income growth exceeding 1.5x Biotechnology median of 4.47%. Joel Greenblatt would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
15.52%
EPS growth exceeding 1.5x Biotechnology median of 9.09%. Joel Greenblatt would investigate advantages.
15.52%
Diluted EPS growth exceeding 1.5x Biotechnology median of 9.52%. Joel Greenblatt would investigate advantages.
3.21%
Share count reduction below 50% of Biotechnology median of 0.51%. Jim Chanos would check for issues.
3.21%
Diluted share reduction below 50% of Biotechnology median of 0.52%. Jim Chanos would check for issues.